eXmoor Pharma co-hosted an evening reception in Boston exploring what it takes to successfully deliver cell and gene therapies, featuring expert insights and a powerful patient perspective.
The CGT Success Blueprint: Strategic Collaboration, Best of Breed Technology, and Scientific Excellence
What does it really take to deliver cell and gene therapies to more patients, faster?
That was the driving question behind this special evening reception in Boston, co-hosted by eXmoor Pharma, Ori Biotech and Kincell Bio.
With expert insight from developers, CDMOs and academic leaders, and a powerful closing Q&A with CAR-T patient Gary Fey, this event brought together the voices shaping the future of CGT manufacturing and strategy.
Moderated by Ori Biotech CEO Jason Foster, the panel explored the practical blueprint for CGT success: strategic collaboration, scientific and operational integration, and the right tools at the right time.
Takeaways from the panel
eXmoor CEO Lucy Foley and Quell Therapeutics’ Aaron Vernon reflected on their six-year collaboration, sharing lessons in building trust, aligning goals, and growing a partnership from consultancy to GMP manufacturing.
You can read more about our collaboration with Quell Therapeutics in this announcement.
“We have a shared vision, and we share the problems as well as the solutions. That takes a different mindset and a lot of dedication from both sides.”
Lucy Foley
CEO, eXmoor Pharma
“We weren’t just looking for a fee-for-service CDMO. We wanted a partner that could go on the journey with us. And we found that in eXmoor.”
Aaron Vernon
Chief Manufacturing Officer, Quell Therapeutics
Other key insights shared by the panel included:
The growing need for flexible manufacturing models that balance early clinical speed with long-term scalability
How academic centres are playing a larger role in translational readiness
The risk of locking in inefficient processes too early, and the need for CMC strategy to be integrated from the start
Why developers and CDMOs must work as a single, aligned team to anticipate bottlenecks and regulatory hurdles
Closing the event was a moving Q&A with CAR-T patient Gary Fey, who shared his personal journey from diagnosis to treatment, including the experience of receiving CAR-T therapy. His reflections reminded everyone in the room of the urgency behind the science and the shared responsibility to make CGT more accessible and scalable.
“The science is amazing. I’m here because of it. But the bigger challenge is making it available to more people.”
Whether you're in early-stage development or scaling up for commercial production, eXmoor Pharma provides the expertise and flexibility you need. Partner with us to move your therapy forward with confidence.
